Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1750-1172
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Limitations of drug registries to evaluate orphan medicinal products for the treatment of lysosomal storage disorders ; volume:6 ; number:1 ; day:16 ; month:4 ; year:2011 ; pages:1-6 ; date:12.2011
Orphanet journal of rare diseases ; 6, Heft 1 (16.4.2011), 1-6, 12.2011
- Creator
-
Hollak, Carla EM
- Contributor
-
Aerts, Johannes MFG
Aymé, Ségolène
Manuel, Jeremy
SpringerLink (Online service)
- DOI
-
10.1186/1750-1172-6-16
- URN
-
urn:nbn:de:1111-2016050119836
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hollak, Carla EM
- Aerts, Johannes MFG
- Aymé, Ségolène
- Manuel, Jeremy
- SpringerLink (Online service)
Other Objects (12)
Registries for orphan drugs: generating evidence or marketing tools?
Rare lysosomal disease registries: lessons learned over three decades of real-world evidence
Recource Registries
Scope and management of Patient Registries for orphan rare disease (ORD) meeting the demands of all involved stakeholders
eRegistries: Electronic registries for maternal and child health
The Orphan
Orphan Island
eRegistries: governance for electronic maternal and child health registries
Efficient Experimental Approach to Evaluate Mass Transfer Limitations for Monolithic DOCs
Secure Linking of Data from Population-Based Cancer Registries with Healthcare Data to Evaluate Screening Programs
7.5 File Format Registries
7.5 File Format Registries
Registries for orphan drugs: generating evidence or marketing tools?
Rare lysosomal disease registries: lessons learned over three decades of real-world evidence
Recource Registries
Scope and management of Patient Registries for orphan rare disease (ORD) meeting the demands of all involved stakeholders
eRegistries: Electronic registries for maternal and child health
The Orphan
Orphan Island
eRegistries: governance for electronic maternal and child health registries
Efficient Experimental Approach to Evaluate Mass Transfer Limitations for Monolithic DOCs
Secure Linking of Data from Population-Based Cancer Registries with Healthcare Data to Evaluate Screening Programs
7.5 File Format Registries
7.5 File Format Registries
Registries for orphan drugs: generating evidence or marketing tools?
Rare lysosomal disease registries: lessons learned over three decades of real-world evidence
Recource Registries
Scope and management of Patient Registries for orphan rare disease (ORD) meeting the demands of all involved stakeholders
eRegistries: Electronic registries for maternal and child health
The Orphan
Orphan Island
eRegistries: governance for electronic maternal and child health registries
Efficient Experimental Approach to Evaluate Mass Transfer Limitations for Monolithic DOCs
Secure Linking of Data from Population-Based Cancer Registries with Healthcare Data to Evaluate Screening Programs
7.5 File Format Registries